SCHEMBL22639581

SCHEMBL22639581

COC(=O)CCC(N)C(=O)OC(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 1/20 0.49
TSHR P16473 3/20 0.43
LMNA P02545 4/20 0.37
KDM4E B2RXH2 1/20 0.37
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
CA12 O43570 3/20 0.34
CA14 Q9ULX7 2/20 0.34
CA9 Q16790 2/20 0.34
CA7 P43166 1/20 0.34
DPP4 P27487 2/20 0.33
DPP8 Q6V1X1 2/20 0.33
DPP9 Q86TI2 2/20 0.33
LTA4H P09960 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
GABRP O00591 2/20 0.32
GABRD O14764 2/20 0.32
GABRA1 P14867 2/20 0.32
GABRB1 P18505 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2241803 0.89 LMNA (0.46) SLC1A1TSHRLMNAKMT2ADPP4
SCHEMBL4537585 0.89 LMNA (0.46) SLC1A1TSHRLMNAKMT2ADPP4
SCHEMBL16523558 0.85 LMNA (0.43) SLC1A1TSHRLMNADPP4DPP8
SCHEMBL1318285 0.84 SLC1A1 (0.55) SLC1A1TSHRLMNAKDM4EKMT2A
SCHEMBL131050 0.84 SLC1A1 (0.55) SLC1A1TSHRLMNAKDM4EKMT2A
SCHEMBL131049 0.84 SLC1A1 (0.55) SLC1A1TSHRLMNAKDM4EKMT2A
SCHEMBL14175423 0.84 CYP1A2 (0.44) SLC1A1LMNAKMT2AGABRPGABRD
SCHEMBL31229067 0.84 CYP1A2 (0.44) SLC1A1LMNAKMT2AGABRPGABRD
Hydrochloric Acid SCHEMBL624146 0.82 SLC1A1 (0.53) SLC1A1TSHRLMNAKDM4EKMT2A
Hydrochloric Acid SCHEMBL1238805 0.82 SLC1A1 (0.53) SLC1A1TSHRLMNAKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10829454-B2 Compositions and methods for the treatment of Parkinson's disease CELLIX BIO PRIVATE LIMITED (IN) 2020-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10829454-B2 Compositions and methods for the treatment of Parkinson's disease PARK7, SNCA, SLC6A3 SLC1A1 523/4885TSHR 2918/4885LMNA 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.